Biotech week ahead, March 9

Biotech stocks rebounded in the week ended March 6, recovering from the previous week’s steep sell-off.
The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news.
The following are key catalysts in the unfolding week that a biotech investor should stay tuned to.

Conferences

Barclays Global Healthcare Conference: March 10-12 in Miami, Florida.
American Academy of Allergy Asthma and Immunology, or AAAAI, Annual Meeting: March 13-16 in Philadelphia, Pennsylvania.

PDUFA Dates

The FDA is set to rule on Bristol-Myers Squibb Co’s BMY 0.23% sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG BAYRY 1.52% and Onyx Pharma’s Nexavar. The PDUFA date has been set for Tuesday.

Clinical Readouts

Blueprint Medicines Corp BPMC 1.8% is scheduled to present at the AAAAI annual meeting with Phase 2 data for Avapritinib, which is being evaluated for treating indolent and smoldering systemic mastocytosis.

Earnings

Monday

• Matinas BioPharma Holdings Inc MTNB 2.75% (before the market open)
• Minerva Neurosciences Inc NERV 0.94% (before the market open)
• BioXcel Therapeutics Inc BTAI 2.77% (before the market open)
• Assertio Therapeutics Inc ASRT 4.59% (after the close)
• SI-Bone Inc SIBN 5.39% (after the close)
• Xenon Pharmaceuticals Inc XENE 6.83% (after the close)
• Organogenesis Holdings Inc ORGO 4.36% (after the close)
• Deciphera Pharmaceuticals Inc DCPH 4.67% (after the close)

Tuesday

• Precision BioSciences Inc DTIL 3.14% (time not provided)
• Akebia Therapeutics Inc AKBA 3.41% (before the market open)
• Catabasis Pharmaceuticals Inc CATB 2.77% (before the market open)
• InspireMD Inc NSPR 3.61% (before the market open)
• ChemoCentryx Inc CCXI 4.38% (after the close)
• CV Sciences Inc CVSI 4.29% (after the close)
• Fulgent Genetics Inc FLGT 7.22% (after the close)
• Sunesis Pharmaceuticals, Inc. SNSS 5.57% (after the close)
• RA Medical Systems Inc RMED 3.37% (after the close)
• Protagonist Therapeutics Inc PTGX 4.59% (after the close)

Wednesday

• Xeris Pharmaceuticals Inc XERS 15.38% (before the market open)
• Liquidia Technologies Inc LQDA 3.12% (before the market open)
• Galmed Pharmaceuticals Ltd GLMD 1.56% (before the market open)
• INmune Bio Inc INMB 0.24% (before the market open)
• Clearside Biomedical Inc CLSD 7.08% (after the close)
• Calithera Biosciences Inc CALA 5.02% (after the close)
• Unity Biotechnology Inc UBX 5.07% (after the close)
• Navidea Biopharmaceuticals Inc NAVB 1.98% (after the close)
• Cumberland Pharmaceuticals, Inc. CPIX 3.72% (after the close)
• BioLife Solutions Inc BLFS 0.5% (after the close)
• Dynavax Technologies Corporation DVAX 0.48% (after the close)
• Miragen Therapeutics Inc MGEN 7.27% (after the close)
• Pfenex Inc PFNX 0.52% (after the close)
• Thursday
• Aquestive Therapeutics Inc AQST 7.73% (before the market open)
• Avadel Pharmaceuticals PLC AVDL 1.79% (before the market open)
• Axsome Therapeutics Inc AXSM 5.26% (before the market open)
• Aldeyra Therapeutics Inc ALDX 1.4% (before the market open)
• Selecta Biosciences Inc SELB 2.03% (before the market open)
• Lexicon Pharmaceuticals, Inc. LXRX 4.07% (before the market open)
• Provention Bio Inc PRVB 3.15% (before the market open)
• Protalix Biotherapeutics Inc PLX 3.42% (before the market open)
• Evofem Biosciences Inc EVFM 1.18% (before the market open)
• China Biologic Products Holdings Inc CBPO 0.51% (before the market open)
• Corbus Pharmaceuticals Holdings Inc CRBP 2.58% (before the market open)
• Pieris Pharmaceuticals Inc PIRS 7.35% (before the market open)
• X4 Pharmaceuticals Inc XFOR 2.4% (before the market open)
• Polarityte Inc PTE 2.33% (before the market open)
• Rubius Therapeutics Inc RUBY 2.5% (before the market open)
• Agenus Inc AGEN (before the market open)
• ADMA Biologics Inc ADMA 6.56% (after the close)
• BioDelivery Sciences International, Inc. BDSI 2.62% (after the close)
• Bellicum Pharmaceuticals Inc BLCM 8.14% (after the close)
• Celcuity Inc CELC 5.51% (after the close)
• Lineage Cell Therapeutics Inc LCTX 3.75% (after the close)
• Chembio Diagnostics Inc CEMI 1.3% (after the close)
• Harpoon Therapeutics Inc HARP 3.99% (after the close)
• Flexion Therapeutics Inc FLXN 2.56% (after the close)
• Neoleukin Therapeutics Inc NLTX 10.96% (after the close)
• Rockwell Medical Inc RMTI 2.59% (after the close)
• Inovio Pharmaceuticals Inc INO 43.78% (after the close)
• Savara Inc SVRA (after the close)
• Ocular Therapeutix Inc OCUL 6.62% (after the close)
• Y-mAbs Therapeutics, Inc YMAB 1.93% (after the close)

Friday

• PLx Pharma Inc PLXP 2.91% (before the market open)
• Achieve Life Sciences Inc ACHV 5.26% (before the market open)

IPOs

Imara, a biopharma company that is developing therapies for rare hemoglobinopathies, has filed to offer 4.45 million shares in an IPO, to be priced between $16 and $18. The company seeks to list its shares on the Nasdaq under the ticker symbol “IMRA.”

IPO Quiet Period Expiry

Revolution Medicines Inc RVMD 3.09%
https://www.benzinga.com/general/biotech/20/03/15492037/the-week-ahead-in-biotech-march-8-14-bristol-myers-awaits-fda-nod-for-liver-cancer-combo-therapy-